アミロイド症治療法の世界市場:全身性アミロイドーシス、その他

LINEで送る

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Systemic amyloidosis – Market size and forecast 2018-2023

Other amyloidosis – Market size and forecast 2018-2023

Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Increasing awareness about rare diseases

Special drug designations

Strategic alliances

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

AbbVie Inc.

Allergan Plc

Alnylam Pharmaceuticals Inc.

Amgen Inc.

Celgene Corp.

GlaxoSmithKline Plc

Ionis Pharmaceuticals Inc.

Johnson & Johnson Services Inc.

Pfizer Inc.

Takeda Pharmaceutical Co. Ltd.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Type – Market share 2018-2023 (%)

Exhibit 19: Comparison by type

Exhibit 20: Systemic amyloidosis – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Systemic amyloidosis – Year-over-year growth 2019-2023 (%)

Exhibit 22: Other amyloidosis – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Other amyloidosis – Year-over-year growth 2019-2023 (%)

Exhibit 24: Market opportunity by type

Exhibit 25: Customer landscape

Exhibit 26: Market share by geography 2018-2023 (%)

Exhibit 27: Geographic comparison

Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 29: North America – Year-over-year growth 2019-2023 (%)

Exhibit 30: Top 3 countries in North America

Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 33: Top 3 countries in Europe

Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: Proportion of geriatric population in Asia 2009 and 2018

Exhibit 36: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 37: Top 3 countries in Asia

Exhibit 38: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 39: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 40: Top 3 countries in ROW

Exhibit 41: Key leading countries

Exhibit 42: Market opportunity

Exhibit 43: Prevalence/incidence of associated risk factors of amyloidosis

Exhibit 44: Growth of geriatric population 2014-2018 (%)

Exhibit 45: Cost of approved drugs for treatment of amyloidosis in the US

Exhibit 46: Impact of drivers and challenges

Exhibit 47: Drug designations

Exhibit 48: Vendor landscape

Exhibit 49: Landscape disruption

Exhibit 50: Vendors covered

Exhibit 51: Vendor classification

Exhibit 52: Market positioning of vendors

Exhibit 53: AbbVie Inc. – Vendor overview

Exhibit 54: AbbVie Inc. – Business segments

Exhibit 55: AbbVie Inc. – Organizational developments

Exhibit 56: AbbVie Inc. – Geographic focus

Exhibit 57: AbbVie Inc. – Key offerings

Exhibit 58: AbbVie Inc. – Key customers

Exhibit 59: Allergan Plc – Vendor overview

Exhibit 60: Allergan Plc – Business segments

Exhibit 61: Allergan Plc – Organizational developments

Exhibit 62: Allergan Plc – Geographic focus

Exhibit 63: Allergan Plc – Segment focus

Exhibit 64: Allergan Plc – Key offerings

Exhibit 65: Allergan Plc – Key customers

Exhibit 66: Alnylam Pharmaceuticals Inc. – Vendor overview

Exhibit 67: Alnylam Pharmaceuticals Inc. – Business segments

Exhibit 68: Alnylam Pharmaceuticals Inc. – Organizational developments

Exhibit 69: Alnylam Pharmaceuticals Inc. – Key offerings

Exhibit 70: Alnylam Pharmaceuticals Inc. – Key customers

Exhibit 71: Amgen Inc. – Vendor overview

Exhibit 72: Amgen Inc. – Business segments

Exhibit 73: Amgen Inc. – Organizational developments

Exhibit 74: Amgen Inc. – Geographic focus

Exhibit 75: Amgen Inc. – Key offerings

Exhibit 76: Amgen Inc. – Key customers

Exhibit 77: Celgene Corp. – Vendor overview

Exhibit 78: Celgene Corp. – Business segments

Exhibit 79: Celgene Corp. – Organizational developments

Exhibit 80: Celgene Corp. – Geographic focus

Exhibit 81: Celgene Corp. – Key offerings

Exhibit 82: Celgene Corp. – Key customers

Exhibit 83: GlaxoSmithKline Plc – Vendor overview

Exhibit 84: GlaxoSmithKline Plc – Business segments

Exhibit 85: GlaxoSmithKline Plc – Organizational developments

Exhibit 86: GlaxoSmithKline Plc – Geographic focus

Exhibit 87: GlaxoSmithKline Plc – Segment focus

Exhibit 88: GlaxoSmithKline Plc – Key offerings

Exhibit 89: GlaxoSmithKline Plc – Key customers

Exhibit 90: Ionis Pharmaceuticals Inc. – Vendor overview

Exhibit 91: Ionis Pharmaceuticals Inc. – Business segments

Exhibit 92: Ionis Pharmaceuticals Inc. – Organizational developments

Exhibit 93: Ionis Pharmaceuticals Inc. – Key offerings

Exhibit 94: Ionis Pharmaceuticals Inc. – Key customers

Exhibit 95: Johnson & Johnson Services Inc. – Vendor overview

Exhibit 96: Johnson & Johnson Services Inc. – Business segments

Exhibit 97: Johnson & Johnson Services Inc. – Organizational developments

Exhibit 98: Johnson & Johnson Services Inc. – Geographic focus

Exhibit 99: Johnson & Johnson Services Inc. – Segment focus

Exhibit 100: Johnson & Johnson Services Inc. – Key offerings

Exhibit 101: Johnson & Johnson Services Inc. – Key customers

Exhibit 102: Pfizer Inc. – Vendor overview

Exhibit 103: Pfizer Inc. – Business segments

Exhibit 104: Pfizer Inc. – Organizational developments

Exhibit 105: Pfizer Inc. – Geographic focus

Exhibit 106: Pfizer Inc. – Segment focus

Exhibit 107: Pfizer Inc. – Key offerings

Exhibit 108: Pfizer Inc. – Key customers

Exhibit 109: Takeda Pharmaceutical Co. Ltd. – Vendor overview

Exhibit 110: Takeda Pharmaceutical Co. Ltd. – Business segments

Exhibit 111: Takeda Pharmaceutical Co. Ltd. – Organizational developments

Exhibit 112: Takeda Pharmaceutical Co. Ltd. – Geographic focus

Exhibit 113: Takeda Pharmaceutical Co. Ltd. – Key offerings

Exhibit 114: Takeda Pharmaceutical Co. Ltd. – Key customers

Exhibit 115: Validation techniques employed for market sizing

Exhibit 116: Definition of market positioning of vendors




※当サイトのレポート紹介カバレッジ
■産業:医療、IT、電子、自動車、産業機械、建設、消費財、食品、化学、材料、エネルギー、金融、サービスなど多様
■地域:世界市場、アジア市場、中国市場、欧州市場、北米市場、中南米市場、中東市場、アフリカ市場など全世界
■レポート種類:市場動向、規模、占有率、トレンド、将来展望、未来予測、業界分析、産業分析、企業分析、事業機会分析、戦略提言など多様